公开(公告)号：WO2014047350A1

公开(公告)日：2014-03-27

申请号：PCT/US2013/060716

申请日：2013-09-19

申请人： MORNINGSIDE TECHNOLOGY VENTURES LTD. ,  NOLIN, Westley B.

发明人： NOLIN, Westley B. ,  NG, Shi Chung ,  DINGES, Jason R. ,  CHAN, Gerald L.

IPC分类号： C12N15/00 ,  A01N63/00 ,  A01N65/00 ,  A61K39/395

CPC分类号： A61K35/768 ,  A61K35/761 ,  A61K35/763 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/10032 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2710/16632 ,  C12N2710/16643 ,  C12N2710/16671 ,  C12N2710/24132 ,  C12N2710/24143 ,  C12N2710/24171 ,  C12N2810/859

摘要： The present disclosure concerns the use of oncolytic viruses for the treatment of cancer. In particular, the use of a herpes simplex virus, a vaccinia virus, or an adenovirus containing a gene encoding a PD-1 binding agent, such as a scFv polypeptide, to achieve a particular degree of oncolysis is described. In some embodiments, the oncolytic virus expressing the PD-1 binding agent is effective at inducing immune responses that kill cancer cells at distant sites from the primary tumor. An oncolytic virus can also be engineered to be less toxic or damaging to non-cancer cells by mutation or modification of gene products such that the alterations render the viruses better able to infect the host, less toxic, and/or better able to selectively infect cancer cells.

摘要翻译： 本公开涉及使用溶瘤病毒治疗癌症。 特别地，描述了使用单纯疱疹病毒，牛痘病毒或含有编码PD-1结合剂（例如scFv多肽）的基因的腺病毒以达到特定程度的溶解。 在一些实施方案中，表达PD-1结合剂的溶瘤病毒在诱导免疫应答方面是有效的，所述免疫应答杀死远处与原发肿瘤的癌细胞。 溶瘤病毒也可以被设计为通过基因产物的突变或修饰来对非癌细胞毒性较小或有害，使得改变使病毒更好地感染宿主，较少毒性和/或更好地选择性感染 癌细胞。